Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma GmbH
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with Valsartan or Valsartan plus HCTZ for 34 weeks with or without respective measures
To demonstrate that supportive measures improve drug adherence in patients with mild essential hypertension treated with valsartan 160 mg or valsartan 160 mg plus HCTZ 12.5 mg for 34 weeks. To assess ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Study to investigate the combination of Afinitor with paclitaxel and carboplatin in advanced large cell lung cancer
The primary objective of this study is to evaluate the efficacy of RAD001 in patients with advanced (stage IV) Lung Cancer (Large Cell) with neuroendocrine differentiation treated with a combination o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Study to compare a tacrolimus Hexal® based regimen versus a Prograf® based regimen in renal transplantation
PHASE I: To demonstrate that the pharmacokinetics of Tacrolimus Hexal® assessed by the ratio of the AUC0-12h over a one month period post-transplantation is comparable to Prograf® in renal transplant...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Full title of the trial : Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with Myfortic® and Sandimmun® Optoral in de novo renal transplant patients
The primary objective of this trial is to show superiority of a CNI-free regimen with respect to the renal function at Month 12 post Tx assessed by glomerular filtration rate – Nankivell method – as c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Study in patients with moderate to severe psoriasis to assess efficacy and safety of secukinumab
To demonstrate that 300 mg secukinumab administered every 2 weeks is superior in achieving PASI 90 at week 32 compared to 300 mg secukinumab every 4 weeks in patients who after treatment with the stan...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
A multicenter, randomized, double-blind, parallel-group study to investigate the glucose lowering effect, safety and tolerability of a 24 week treatment with Vildagliptin 100 mg o.a.d. versus placebo followed by a 12 week treatment period with open-label Vildagliptin 100 mg o.a.d. as add-on therapy in patients with type 2 diabetes inadequately controlled with Metformin monotherapy
To confirm the efficacy of vildagliptin 100 mg add-on therapy in patients with type 2 diabetes inadequately controlled with prior metformin monotherapy by testing the hypothesis that the HbA1c reducti...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
A 12 week treatment, open-label, multicenter study to investigate the efficacy and safety of valsartan 160-320 mg with regard to effects on lipid subfractions in hypertensive patients with metabolic syndrome
To demonstrate that valsartan 320 mg has a positive effect on small, dense LDL subfractions (LDL 5+6) in hypertensive patients with metabolic syndrome after 12 weeks of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser treatment vs. laser treatment alone in Proliferative Diabetic Retinopathy
Change of area of neovascularizations as measured by Fluorescein Angiography at month 12 (difference to baseline value).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
An uncontrolled, multicenter 12 month long term study on skin reconstitution with Elidel® (pimecrolimus) 1% cream in adult patients with atopic eczema and corticosteroid induced skin damage
To investigate the reconstitution of steroid damaged skin with pimecrolimus 1% cream by the decrease of the Dermatophot® score from baseline to end of the study.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
A clinical study to evaluate the safety and benefit from using Everolimus and Exemestane in combination in postmenopausal women with estrogen receptor positive breast cancer
To assess the Overall Response Rate (ORR) in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with NSAIs treated with the combination of Everolimus...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant